Last reviewed: June 4, 2026
Last updated: June 4, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide and tirzepatide represent two distinct approaches to weight loss through hormone therapy. Semaglutide targets the glucagon-like peptide-1 receptor, while tirzepatide activates both GLP-1 and glucose-dependent insulinotropic peptide (GIP) pathways simultaneously. Clinical evidence shows tirzepatide users typically lose 15-22% of body weight, compared to 10-17% for semaglutide users over 68 weeks.
How Semaglutide and Tirzepatide Work Differently
Semaglutide functions as a GLP-1 receptor agonist, signaling your brain to reduce hunger, slow stomach emptying, and improve blood sugar control. This single-pathway mechanism has demonstrated consistent weight loss outcomes in millions of users. The medication mimics a natural hormone your pancreas produces, making it a well-tolerated option for most patients.
Tirzepatide operates through dual activation—it stimulates both GLP-1 and GIP receptors in your brain and gut. This two-pathway approach influences appetite suppression, energy expenditure, and glucose metabolism through independent mechanisms. Because tirzepatide engages additional biological systems, some patients experience more pronounced appetite reduction and metabolic changes than with single-pathway therapy alone.
Weight Loss Results: Direct Clinical Evidence
The SUSTAIN trial family tracked semaglutide users for 68 weeks, documenting average weight loss ranging from 10% to 17% of starting body weight depending on maintenance dose. These results established semaglutide as highly effective for chronic weight management. Real-world data has consistently aligned with trial outcomes, with most users seeing steady progress over 4-6 months of treatment.
The SURMOUNT trial series evaluated tirzepatide across three separate studies, with participants losing 15% to 22% of body weight over the same 68-week period. Head-to-head comparisons within SURMOUNT-2 showed tirzepatide users lost approximately 5-7 pounds more than semaglutide users when both groups reached their highest tolerated doses. These differences remained statistically significant across nearly all measured timepoints.
Side Effects and Tolerability Comparison
Both medications share common gastrointestinal side effects including nausea, vomiting, constipation, and diarrhea. These effects typically peak during dose escalation and diminish as your body adapts. Most users report that side effects are manageable and temporary, with the majority choosing to continue treatment because weight loss benefits outweigh initial discomfort.
Tirzepatide users report slightly higher rates of nausea during the first 2-4 weeks compared to semaglutide users, though this rarely leads to discontinuation. Pancreatitis risk remains rare with both medications and is not elevated above baseline population rates. Patients with personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 should avoid both GLP-1 and GIP agonists due to preclinical safety signals in rodent studies.
Cost, Access, and Personalization at PlexusDx
PlexusDx offers compounded semaglutide injection starting at $149 per month and tirzepatide injection starting at $249 per month through licensed 503A pharmacies. No insurance is required, no membership fees apply, and both HSA and FSA accounts cover these medications. Your dose may need to go up over time. Your price won't—pricing remains flat regardless of dose escalation across all three commitment tiers.
PlexusDx's Precision Peptide Genetic Test ($99 add-on after your first treatment month) identifies how your unique genetics influence GLP-1R and GIPR pathway sensitivity. Testing analyzes variants like GLP1R rs6923761 and GIPR rs1800437 across 14 metabolic pathways and 49 peptide functions. This personalized insight helps determine whether you'll respond optimally to single-pathway semaglutide or benefit more from dual-pathway tirzepatide therapy, informed by your individual biological profile.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Will I lose more weight on tirzepatide than semaglutide?
Clinical trials show tirzepatide users typically lose 5-7 pounds more than semaglutide users by week 68. However, individual results vary significantly based on genetics, lifestyle, and metabolism. PlexusDx's Precision Peptide Genetic Test can help predict which pathway approach aligns with your genetic predispositions.
What does the research actually say about these two medications?
The SUSTAIN series (semaglutide) documented 10-17% weight loss, while SURMOUNT series (tirzepatide) documented 15-22% weight loss over 68 weeks. Tirzepatide's dual-pathway mechanism showed superior outcomes in direct comparisons within SURMOUNT-2. Both are considered first-line agents in major obesity treatment guidelines.
How much does tirzepatide cost at PlexusDx compared to semaglutide?
Compounded tirzepatide injection starts at $249 per month, while compounded semaglutide injection starts at $149 per month. Both pricing tiers remain flat regardless of dose increases—you'll never pay more simply because your dose escalates. Both are HSA/FSA eligible and available in all 50 states without insurance.
Are tirzepatide's side effects worse than semaglutide's?
Both share similar gastrointestinal side effects, though tirzepatide users report slightly more nausea during initial dosing. Side effects typically diminish within 2-4 weeks as your body adapts. Serious adverse events remain rare with both medications, and tolerability improves significantly after the titration phase.
Can genetics help me choose between semaglutide and tirzepatide?
Yes. PlexusDx's Precision Peptide Genetic Test analyzes your GLP1R and GIPR variants along with 14 metabolic pathways to predict pathway sensitivity. Certain genetic profiles suggest stronger GLP-1R responsiveness, while others indicate GIP pathway activation may enhance outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Do Ozempic Make You Lose Weight? Understanding the Connection
Will Insurance Cover Semaglutide for Weight Loss?